Skip to content

Efficacy and Safety of Digital Therapeutic in Adults With Prediabetes

Open-Label, Randomized, Controlled, Parallel Group Study Evaluating Efficacy and Safety of Digital Therapeutic (TH-001) for the Treatment of Prediabetes in Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05668819
Enrollment
68
Registered
2022-12-30
Start date
2023-02-07
Completion date
2024-12-24
Last updated
2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes

Keywords

Prediabetic State, Digital Therapeutic, Mobile Health, Digital Health, Mobile Apps, Lifestyle Modification, mHealth

Brief summary

The study aims to evaluate the efficacy and safety of a digital therapeutic (TH-001) for adult individuals with prediabetes.

Interventions

DEVICETH-001

TH001 is a software program intended to treat adults with prediabetes.

Sponsors

Tesu Saglik Teknolojileri A.S.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open-Label, Randomized, Controlled

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Being diagnosed with prediabetes according to the ADA Prediabetes Diagnostic Criteria (the presence of at least one of the following criteria is sufficient for diagnosis: FBG 100 - 125 mg/dL, OGTT 2 hour BG: 140 - 199 mg/dL, HbA1c: 5.7% - 6.4) * Not using medication for the treatment of prediabetes, and if so, taking a break for at least two weeks * Having a smartphone with an iOS or Android operating system * Being able to use a mobile application

Exclusion criteria

* Being diagnosed with diabetes mellitus * Having a disease that can cause prediabetes * Taking medication that may cause prediabetes

Design outcomes

Primary

MeasureTime frameDescription
Change in HbA1c90 daysThe difference in the mean change from baseline in HbA1c (%) at Day 90 between groups.
Change in FPG90 daysThe difference in the mean change from baseline in FPG (mg/dL) at Day 90 between groups.
Change in PPG90 daysThe difference in the mean change from baseline in 2-hour 75 g OGTT (mg/dL) at Day 90 between groups.

Secondary

MeasureTime frameDescription
Change in weight90 daysThe difference in the mean change from baseline in weight (kg) at Day 90 between groups.
Change in WHR90 daysThe difference in the mean change from baseline in waist-to-hip ratio (WHR) (waist circumference and hip circumference measured in centimeters) at Day 90 between groups.
Change in BMI90 daysThe difference in the mean change from baseline in BMI (kg/m\^2) at Day 90 between groups.
Change in WC90 daysThe difference in the mean change from baseline in Waist Circumference (centimeters) at Day 90 between groups.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026